Literature DB >> 9120716

Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas.

I K Bukholm1, J M Nesland, R Kåresen, U Jacobsen, A L Børresen.   

Abstract

Alterations in the p53 protein are a common feature in most malignancies, including breast carcinomas. p53 protein alterations contribute to malignant transformation in several ways, through genomic instability and accumulation of additional genetic alterations in other genes, through alteration of the p53-dependent apoptotic pathway, and through downregulation of downstream effector proteins such as p21 (WAF1/CIP1), necessary for cell-cycle growth arrest. Cell-cycle arrest is needed to allow DNA repair after injury. This study examines the relationship between abnormalities in p53 protein and expression of p21 protein in 70 cases selected from a series of 212 sporadic human breast carcinomas. Immunohistochemistry (IHC) was used for detection of p53 and p21 protein expression. Constant denaturant gel electrophoresis (CDGE) was used for detection of mutations in exons 5-8 of the TP53 gene. A highly significant association was found between abnormalities in p53, scored as protein accumulation and/or mutations, and lack of p21 expression. p21 was also shown to be downregulated in samples without p53 alterations, indicating that other mechanisms are also involved in turning off this gene.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120716     DOI: 10.1002/(SICI)1096-9896(199702)181:2<140::AID-PATH745>3.0.CO;2-A

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  16 in total

1.  Different gene expression patterns in invasive lobular and ductal carcinomas of the breast.

Authors:  Hongjuan Zhao; Anita Langerød; Youngran Ji; Kent W Nowels; Jahn M Nesland; Rob Tibshirani; Ida K Bukholm; Rolf Kåresen; David Botstein; Anne-Lise Børresen-Dale; Stefanie S Jeffrey
Journal:  Mol Biol Cell       Date:  2004-03-19       Impact factor: 4.138

2.  Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival.

Authors:  A N Jain; K Chin; A L Børresen-Dale; B K Erikstein; P Eynstein Lonning; R Kaaresen; J W Gray
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

Review 3.  Molecular cues on obesity signals, tumor markers and endometrial cancer.

Authors:  Danielle Daley-Brown; Gabriela M Oprea-Ilies; Regina Lee; Roland Pattillo; Ruben R Gonzalez-Perez
Journal:  Horm Mol Biol Clin Investig       Date:  2015-01

Review 4.  Molecular chemotherapy for breast cancer.

Authors:  A Patterson; A L Harris
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

5.  Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.

Authors:  Issa F Khouri; Roland Bassett; Nancy Poindexter; Susan O'Brien; Carlos E Bueso-Ramos; Yvonne Hsu; Alessandra Ferrajoli; Michael J Keating; Richard Champlin; Marcelo Fernandez-Vina
Journal:  Cancer       Date:  2011-03-31       Impact factor: 6.860

6.  p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis.

Authors:  M J Pellikainen; T T Pekola; K M Ropponen; V V Kataja; J K Kellokoski; M J Eskelinen; V-M Kosma
Journal:  J Clin Pathol       Date:  2003-03       Impact factor: 3.411

7.  Decorin inhibits proliferation and metastasis in human bladder cancer cells by upregulating P21.

Authors:  Hongjie Chen; Ziyi Wang; Ninggang Yang; Jun Zhang; Zhong Liang
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

Review 8.  P21 and p27: roles in carcinogenesis and drug resistance.

Authors:  Abde M Abukhdeir; Ben Ho Park
Journal:  Expert Rev Mol Med       Date:  2008-07-01       Impact factor: 5.600

9.  A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide.

Authors:  Sharon A Glynn; Brenda J Boersma; Tiffany M Howe; Hege Edvardsen; Stephanie B Geisler; Julie E Goodman; Lisa A Ridnour; Per E Lønning; Anne-Lise Børresen-Dale; Bjorn Naume; Vessela N Kristensen; Stephen J Chanock; David A Wink; Stefan Ambs
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

10.  Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.

Authors:  Lars O Baumbusch; Simen Myhre; Anita Langerød; Anna Bergamaschi; Stephanie B Geisler; Per E Lønning; Wolfgang Deppert; Irene Dornreiter; Anne-Lise Børresen-Dale
Journal:  Mol Cancer       Date:  2006-10-20       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.